Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | APAF1 | O14727 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL378551 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL7856022 | 0.73 | TSHR (0.42) | TSHRKMT2AALDH1A1CYP2A6 | |
| SCHEMBL2954425 | 0.70 | TSHR (0.37) | HDAC8TSHRALDH1A1CYP2A6 | |
| SCHEMBL9355736 | 0.69 | TSHR (0.33) | TSHRKMT2AALDH1A1 | |
| SCHEMBL1258038 | 0.66 | ABCC1 (0.41) | HDAC8TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL14152645 | 0.66 | CHRNA1 (0.33) | — | |
| SCHEMBL943724 | 0.65 | — | — | |
| SCHEMBL26256153 | 0.65 | — | — | |
| SCHEMBL11325428 | 0.65 | — | — | |
| SCHEMBL898960 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666870-B2 | Phthalazinone derivatives | MAYBRIDGE LIMITED (GB) | 2010-02-23 | — | — | US | disclosed |
| US-20090163477-A1 | PHTHALAZINONE DERIVATIVES | MAYBRIDGE LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| US-7407957-B2 | e.g. 4-[5-(piperazine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent; septic shock; ischemic injury; reperfusion injury; hemorrhagic shock; and multiple sclerosis | MAYBRIDGE LIMITED (GB) | 2008-08-05 | — | — | US | disclosed |
| WO-2006021801-A1 | 4-HETEROARYLMETHYL SUBSTITUTED PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163477-A1 | PHTHALAZINONE DERIVATIVES | PARP1, PARP2, PARP11 | HDAC8 79/4885TSHR 849/4885KCNH2 3922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.